NovoCure Ltd (NVCR) stock forecast and price target
Price $11.83 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($11.83)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-1.05 | +13.7% | $740M |
| Next fiscal year ends December 31, 2027 | $-0.73 | +30.9% | $809M |
| Next quarter ends December 31, 2026 | $-0.21 | +2.7% | $190M |
| Quarter after ends March 31, 2027 | $-0.20 | +68.5% | $189M |
Consensus of the analysts covering NovoCure, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 121.0% upside over 12 months. Our discounted cash flow model with moderate assumptions puts NovoCure’s intrinsic value about 81% below today’s market value, and it scores 0.8 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the NovoCure stock price target?
The average 12-month target from 7 analysts is $26.14, 121.0% above the current price of $11.83 Targets range from $15.00 to $52.00.
Is NovoCure a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 3 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is NovoCure expected to earn?
Analysts expect EPS of $-1.05 for the fiscal year ending December 31, 2026 and $-0.73 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.